Abingdon Health (LSE:ABDX) reported a 30% rise in revenue to £11.0m for the year to 30 June 2026 and a narrower adjusted EBITDA loss of £1.5m, including a small profit in the second half. However, revenue in the first quarter of its new financial year was below the directors' expectations, and the accounts disclose a material uncertainty over going concern.
What was announced
AIM-quoted Abingdon Health plc, a contract developer and manufacturer of lateral flow diagnostics that also provides regulatory services, published final results for the year ended 30 June 2026 (FY26) on 13 October 2026.
Reported revenue increased 30% to £11.0m (FY25: £8.4m). Including grant income, total revenue was £11.3m, up 32% from £8.6m. Executive Chairman Dr Chris Hand said: "We still expect to deliver significant growth in FY27 and beyond."
The numbers
Contract development was the largest contributor, with revenue up 56% to £5.0m (FY25: £3.2m). Regulatory services and MedTech consulting grew 21% to £4.1m, contract manufacturing was flat at £1.3m and product sales were £0.6m (£0.5m). By geography, UK revenue fell to £2.8m from £4.5m, while Europe rose to £4.2m (£1.7m) and the USA and Canada to £3.8m (£2.1m).
Gross profit was £5.2m (FY25: £3.7m), with gross margin improving to 47.1% from 44.3%. The adjusted EBITDA loss narrowed to £1.5m from £2.6m. Performance was weighted to the second half: H2 revenue was £6.8m against £4.2m in H1, and adjusted EBITDA swung from a £1.7m loss in the first half to a £0.2m profit in the second.
Loss before tax narrowed to £2.0m (FY25: £3.5m), and the loss for the year was £2.1m (£3.4m) after a tax charge of £106k. Basic and diluted loss per share was 0.51p (0.93p). Cash stood at £2.9m at 30 June 2026 (£1.9m), helped by a £3.2m net fundraise in October 2025, with £0.7m outstanding on an Innovate UK loan.
Going concern and current trading
The directors reported "a material uncertainty which may cast significant doubt" on the group's ability to continue as a going concern, and the auditor drew attention to this without modifying its opinion. The directors modelled a downside scenario with revenue about 15% below expectations, with mitigations including reduced discretionary spending, deferred recruitment and working capital management. The announcement notes that further financing may be needed and is not committed.
Revenue in the first quarter of FY27 was below the directors' expectations, which the company attributed mainly to delays on some customer programmes that limited revenue recognition and milestone invoicing. Factors cited included specialist reagent availability, specification updates and some projects being replaced by others. The directors expect most of this revenue to be recovered later in the year, meaning revenue and adjusted EBITDA will be weighted to the second half, with first-half cash flow affected. Revenue from FOFH has been deferred while that customer's fundraise continues, and a restructuring at CS Lifesciences is expected to affect full-year revenue, though the company expects a smaller EBITDA impact.
Outlook and what to watch next
The board expects continued revenue growth to deliver an improved adjusted EBITDA position in FY27 compared with FY26; this is company guidance and no numerical range was given. Commercial developments during the year included £4.8m of multiplex lateral flow development contracts announced in March 2026, a US$2m semi-quantitative multiplex contract, the UK launch of Upfront Diagnostics' LVOne stroke triage test, for which Abingdon is CDMO partner, and the opening of an expanded site in Madison, Wisconsin on 24 September 2026.
Key points to monitor include recovery of delayed Q1 revenue, cash flow through the first half and any further financing. The AGM date was not stated in the announcement.






Please wait processing your request...